Roche’s Gazyvaro approved in Europe for patients with the most common type of leukemia
29 July 2014 | By Roche
Roche announced that the European Commission has approved Gazyvaro (obinutuzumab) in combination with chlorambucil chemotherapy...
List view / Grid view
News
IMBRUVICA® (ibrutinib) receives regular approval by U.S. FDA in chronic lymphocytic leukemia (CLL) and CLL patients with del 17p
29 July 2014 | By Johnson & Johnson
The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for IMBRUVICA® (ibrutinib) capsules for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.1 The FDA also approved IMBRUVICA for CLL patients with del 17p,1 a genetic…
Novartis vaccine Bexsero® sees high uptake in first large-scale public vaccination program to help protect against devastating meningitis B
29 July 2014 | By Novartis
Novartis has announced the initial results of a large-scale vaccination campaign with Bexsero® to help protect against meningitis B within the Saguenay-Lac-Saint-Jean region of Québec, Canada...
Abbott to showcase innovations to help labs solve health care challenges at the American Association for Clinical Chemistry Lab Expo
Clinical laboratories around the world are helping to improve patient care while navigating an evolving healthcare environment. To help laboratories with increasing demands, Abbott (NYSE: ABT) is developing diagnostic solutions for today and tomorrow, which it will showcase during the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical…
AstraZeneca and Roche announce partnership to develop companion diagnostic test for AZD9291
28 July 2014 | By AstraZeneca
AstraZeneca announced it has entered into collaboration with Roche to develop a plasma-based companion diagnostic test to support AZD9291...
Alcon’s Simbrinza® approved in the EU to treat patients living with glaucoma, a chronic sight-threatening eye disease
28 July 2014 | By Novartis
Alcon, the global leader in eye care and a division of Novartis, announced that Simbrinza® eye drops suspension (brinzolamide 10mg/mL and brimonidine tartrate 2mg/mL) has been approved by the European Commission...
FT Global Pharmaceutical and Biotechnology Conference
28 July 2014 | By FT Live
The future is arriving fast for the life science industry...
FDA approves Flonase allergy relief for sale over-the-counter in the United States
25 July 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the U.S. Food and Drug Administration has approved Flonase® Allergy Relief (fluticasone propionate 50 mcg spray)...
Gilead announces new agreement with Medicines Patent Pool for access to medicines in developing world countries
Gilead Sciences, Inc. (NASDAQ:GILD) announced today at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool (MPP) to expand access to Gilead’s investigational drug tenofovir alafenamide (TAF) for HIV and hepatitis B, contingent on the medicine’s U.S. regulatory approval.
Roche with good half year performance
24 July 2014 | By Roche
Pharmaceutical giant Roche delivers its first-half results for 2014...
FDA accepts Sandoz application for biosimilar filgrastim
24 July 2014 | By Novartis
Sandoz announced that the US Food and Drug Administration has accepted its Biologics License Application for filgrastim...
PLEGRIDY™ (Peginterferon beta-1a) approved in the European Union for the treatment of multiple sclerosis
24 July 2014 | By Biogen Idec
Biogen Idec announced that the European Commission has granted marketing authorization for PLEGRIDYTM (peginterferon beta-1a)...
Merck initiates Phase 3 study of Letermovir, an investigational antiviral for prevention of cytomegalovirus (CMV) infection in high-risk bone marrow transplant patients
24 July 2014 | By Merck
Merck announced that the first patient has been enrolled in a global Phase 3 clinical study of letermovir (MK-8228)...
Heart patients in England and Wales offered more choice of therapies as NICE extends recommendations for prasugrel
24 July 2014 | By Eli Lilly and Company & Daiichi Sankyo
Revised guidance from the National Institute for Health and Care Excellence, recommends once-daily, oral antiplatelet prasugrel (Efient®)...
Sucampo announces publication of NICE recommendation for AMITIZA® (Lubiprostone)
23 July 2014 | By Sucampo Pharmaceuticals, Inc
Sucampo Pharmaceuticals, Inc. announced that the United Kingdom’s National Institute of Health and Care Excellence has published the technology appraisal guidance recommending the use of AMITIZA® (lubiprostone)...
